- Company
- Tabrecta is scheduled to be introduced in August
- by Eo, Yun-Ho Jul 20, 2022 05:50am
- MET anticancer drugs will enter the first stage of registration of insurance benefits. According to related industries, Tabrecta will be introduced to the HIRA Cancer Disease Review Committee on August 10. Tabrecta was approved in Korea in November last year as a non-small cell Lung Cancer (NSCLC) treatment that confirmed MET Exxon 14 deficie
- Company
- Moderna to soon release bivalent COVID-19 vaccine
- by Jul 20, 2022 05:49am
- Moderna is determined to promptly commercialize its new bivalent COVID-19 vaccine “mRNA-1273.214 (214)” in Korea. On the morning of the 19th, Moderna held a “Moderna’s mRNA technology and strategy in the endemic era” press conference at JW Mariott Hotel. At the conference, the company stated that it can “supply the 214 globally by the
- Company
- Big Pharma are making all efforts to preoccupy orphan drugs
- by Jul 20, 2022 05:49am
- New drugs are emerging one after another for rare diseases such as multiple Castleman's disease, beta thalassemia, Fabri's disease, and spinal muscular dystrophy, which were not well known and had no medicine. Global pharmaceutical companies such as Johnson & Johnson, AstraZeneca, and Roche are leading new drugs for rare diseases. It was suggest
- Company
- Maximizing JW Pharma's platform technology
- by Chon, Seung-Hyun Jul 20, 2022 05:48am
- JW Group is implementing an active open innovation strategy to maximize R&D capabilities. In order to boost the potential of two core platform technologies developed by themselves, they are mobilizing all resources that can be utilized from domestic bio ventures to overseas investment institutions. According to industries on the 13th, JW Grou
- Company
- Novartis nears reimb for its 2 ultra-high-priced new drugs
- by Eo, Yun-Ho Jul 19, 2022 05:16am
- With Novartis Korea nearing reimbursement listing for its 2 ultra high-priced drugs, how the two drugs will progress is receiving attention. The two Novartis drugs that have continuously raised issues since its domestic approval are ‘Kymriah (tisagenlecleucel) and Zolgensma (onasemnogene abeparvovec-xioi). Among the two drugs, Kymirah was fi
- Company
- Daiichi Sankyo's CSR activities resumed in 3 years
- by Lee, Seok-Jun Jul 19, 2022 05:16am
- As ESG management has recently emerged as a hot topic, corporate social responsibility (CSR) activities are also drawing attention. ESG and CSR are different, but they are evaluated to be similar in large concepts. All are based on the premise that voluntary participation of CEOs and executives and employees should precede. ESG and CSR are di
- Company
- Samsung Bioepis announces effectiveness of Lucentis Similar
- by Kim, Jin-Gu Jul 19, 2022 05:16am
- Samsung Bioepis announced on the 18th that it has announced the results of research on the ophthalmic disease treatment "SB11 (Lucentis biosimilar, Ranibizumab)" at the ASRS conference held in New York from the 13th to the 16th (local time). Samsung Bioepis released the results of post-hoc analysis of phase 3 clinical data for macular dege
- Company
- NTS will provide tax support for bio companies
- by Kang, Shin-Kook Jul 19, 2022 05:15am
- Biopharmaceutical companies are set to receive tax support from the National Tax Service. The National Tax Service (Commissioner Chang-ki Kim) held a roundtable meeting at the Incheon Free Economic Zone located in Songdo, Incheon to listen to the difficulties experienced by those in the field with leaders of small-to-mid-sized enterprises
- Company
- Will social distancing resume?
- by Kim, Jin-Gu Jul 19, 2022 05:15am
- As the spread of the coronavirus is intensifying again, concerns in the pharmaceutical bio industry are also growing. Front-line companies seem to be paying keen attention to whether to resume social distancing measures, while asking executives and employees to strengthen personal quarantine rules ahead of the full-fledged summer vacation sea
- Company
- GC WellBeing transfers raw materials technology to Japan
- by Jul 18, 2022 06:06am
- GC Wellbeing (CEO Kim Sang-hyun) announced on the 15th that it has signed a technology transfer contract with Japan's Healthy Navi for the functional raw material Green-Cera F. Healthy Navi is a company in charge of product development and distribution of functional and general food ingredients in Japan. Green-Cera F is a raw material recogni
